Compare Alphabet Inc Class A (GOOGL) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs McKesson Corporation — how do they compare? Alphabet Inc Class A trades at $351.66 (market cap $4.24T), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: Alphabet Inc Class A is far larger — about 39.1× McKesson Corporation's market cap, and McKesson Corporation pays the higher dividend (0.4%). Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and McKesson Corporation for 74 Days on average.
| GOOGL | MCK | |
|---|---|---|
Market Cap | $4.24T | $108.46B |
Volume | 23,392,850 | 712,607 |
Sector | Media | Health |
52-Week High | $402.62 | $995.69 |
52-Week Low | $236.59 | $725.17 |
Typical Hold Time | 85 Days | 74 Days |
Enterprise Value | $4.13T | $115.00B |
Dividend Yield | 0.25% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $348.29, down 0.63% on the day, with strong technical support at $346 and resistance at $352. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving a 32.8% profit margin. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $9.11 surpassing the $2.87 estimate. Analyst consensus remains overwhelmingly bullish with 87% buy ratings and a $431.83 price target, representing 24% upside potential.
Alphabet presents a compelling investment case driven by AI leadership, strong cash flow generation, and consistent earnings outperformance. Key risks include regulatory scrutiny, competitive pressures in search and cloud, and market volatility. The stock's current valuation at 17.48x P/E appears reasonable given growth prospects, while technical indicators suggest near-term consolidation within a defined trading range.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
